FEDERAL COURT OF AUSTRALIA
Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC (No 3)
[2006] FCA 1797
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826) v WARNER-LAMBERT COMPANY LLC AND COMMISSIONER OF PATENTS
VID 926 OF 2005YOUNG J
20 DECEMBER 2006
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 926 OF 2005
BETWEEN:
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
Applicant/Cross-RespondentAND:
WARNER-LAMBERT COMPANY LLC
First Respondent/Cross-ClaimantCOMMISSIONER OF PATENTS
Second Respondent
JUDGE:
YOUNG J
DATE OF ORDER:
20 DECEMBER 2006
WHERE MADE:
MELBOURNE
THE COURT FURTHER ORDERS THAT:
3.Order 1 of the orders made by the Court this day be stayed until:
(a)Friday 9 February 2007; or
(b)if an appeal from these orders is lodged on or before Friday 9 February 2007, the determination of that appeal or further order.
4.The time for filing any notice of appeal be extended to 9 February 2007.
5.The applicant/cross-respondent pay the first respondent/cross-claimant’s costs of and incidental to the cross claim.
6.The first respondent/cross-claimant pay to the applicant/cross-respondent 60 per cent of the applicant/cross-respondent’s costs of and incidental to the amended application, including the costs of and incidental to the notice of motion dated 24 May 2006.
7.The applicant/cross-respondent pay the first respondent/cross-claimant’s costs of and incidental to the notices of motion dated 20 October 2005 and 18 April 2006.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 926 OF 2005
BETWEEN:
RANBAXY AUSTRALIA PTY LTD (ACN 110 871 826)
Applicant/Cross-RespondentAND:
WARNER-LAMBERT COMPANY LLC
First Respondent/Cross-ClaimantCOMMISSIONER OF PATENTS
Second Respondent
JUDGE:
YOUNG J
DATE:
20 DECEMBER 2006
PLACE:
MELBOURNE
REASONS FOR JUDGMENT
The effect of my decision in Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 2) [2006] FCA 1787 (‘Ranbaxy (No 2)’) is that the applicant/cross-respondent, Ranbaxy Australia Pty Ltd (‘Ranbaxy’), has obtained the relief it sought by its amended application, and the first respondent/cross-claimant, Warner-Lambert Company LLC (‘Warner Lambert’) has obtained the primary relief it sought by its cross claim. After I delivered judgment, I invited the parties to make submissions on the issue of costs and other orders.
COSTS
The general principles governing the question of costs are not in doubt: see Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495 at 497-498 [10]; and Koninklijke Philips Electronics NV v Remington Products Australia Pty Ltd (1999) 45 IPR 634 at 639 [17]. In the absence of special circumstances, the ordinary rule is that the costs of each claim should respectively follow the event of each claim.
Ranbaxy accepts that the ordinary rule should apply to Warner-Lambert’s cross claim in respect of which I have made an injunctive order. Accordingly, I will order that Ranbaxy pay Warner-Lambert’s costs of and incidental to Warner-Lambert’s cross claim.
With regard to Ranbaxy’s amended application, Ranbaxy concedes that there are special circumstances that warrant a departure from the ordinary rule…
Keep reading for free
Create a free CaseChat account to read Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] FCA 1797
- Decision Date
CaseChat Overview and Summary
Justice Young concluded that the ordinary rule of costs should apply, with Ranbaxy paying Warner-Lambert’s costs for the cross claim. Regarding Ranbaxy’s amended application, Justice Young found special circumstances warranted a departure from the ordinary rule. Ranbaxy had abandoned three grounds of invalidity shortly before the trial, leading to wasted costs. However, Justice Young determined that Ranbaxy’s costs should be reduced by 40% rather than ordering Warner-Lambert to pay Ranbaxy’s costs. Warner-Lambert was awarded the costs of two notices of motion, while Ranbaxy was to bear the costs of the third, given the lack of practical success. The court also made orders to stay the revocation of the Enantiomer Patent pending appeal and to extend the time for filing an appeal notice.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: YOUNG J
Full text does not contain this section.